Clinical Cholera Surveillance Sensitivity in Bangladesh and Implications for Large-Scale Disease Control.
Bangladesh
cholera
disease control
elimination
surveillance
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
pubmed:
29
8
2021
medline:
27
1
2022
entrez:
28
8
2021
Statut:
ppublish
Résumé
A surveillance system that is sensitive to detecting high burden areas is critical for achieving widespread disease control. In 2014, Bangladesh established a nationwide, facility-based cholera surveillance system for Vibrio cholerae infection. We sought to measure the sensitivity of this surveillance system to detect cases to assess whether cholera elimination targets outlined by the Bangladesh national control plan can be adequately measured. We overlaid maps of nationally representative annual V cholerae seroincidence onto maps of the catchment areas of facilities where confirmatory laboratory testing for cholera was conducted, and we identified its spatial complement as surveillance greyspots, areas where cases likely occur but go undetected. We assessed surveillance system sensitivity and changes to sensitivity given alternate surveillance site selection strategies. We estimated that 69% of Bangladeshis (111.7 million individuals) live in surveillance greyspots and that 23% (25.5 million) of these individuals live in areas with the highest V cholerae infection rates. The cholera surveillance system in Bangladesh has the ability to monitor progress towards cholera elimination goals among 31% of the country's population, which may be insufficient for accurately measuring progress. Increasing surveillance coverage, particularly in the highest risk areas, should be considered.
Sections du résumé
BACKGROUND
A surveillance system that is sensitive to detecting high burden areas is critical for achieving widespread disease control. In 2014, Bangladesh established a nationwide, facility-based cholera surveillance system for Vibrio cholerae infection. We sought to measure the sensitivity of this surveillance system to detect cases to assess whether cholera elimination targets outlined by the Bangladesh national control plan can be adequately measured.
METHODS
We overlaid maps of nationally representative annual V cholerae seroincidence onto maps of the catchment areas of facilities where confirmatory laboratory testing for cholera was conducted, and we identified its spatial complement as surveillance greyspots, areas where cases likely occur but go undetected. We assessed surveillance system sensitivity and changes to sensitivity given alternate surveillance site selection strategies.
RESULTS
We estimated that 69% of Bangladeshis (111.7 million individuals) live in surveillance greyspots and that 23% (25.5 million) of these individuals live in areas with the highest V cholerae infection rates.
CONCLUSIONS
The cholera surveillance system in Bangladesh has the ability to monitor progress towards cholera elimination goals among 31% of the country's population, which may be insufficient for accurately measuring progress. Increasing surveillance coverage, particularly in the highest risk areas, should be considered.
Identifiants
pubmed: 34453539
pii: 6359020
doi: 10.1093/infdis/jiab418
pmc: PMC8687068
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S725-S731Subventions
Organisme : NIAID NIH HHS
ID : R01 AI135115
Pays : United States
Organisme : ACL HHS
ID : U01GH001207
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet Microbe. 2020 Dec;1(8):e336-e343
pubmed: 33345203
Am J Trop Med Hyg. 2016 Mar;94(3):537-543
pubmed: 26755564
PLoS Med. 2017 Jan 17;14(1):e1002218
pubmed: 28095468
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):579-583
pubmed: 28594790
PLoS Negl Trop Dis. 2018 Mar 14;12(3):e0006286
pubmed: 29538377
PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007124
pubmed: 30703097
Clin Infect Dis. 2020 Oct 23;71(7):1635-1642
pubmed: 31891368
Int J Infect Dis. 2020 Oct;99:69-74
pubmed: 32721530
Int J Epidemiol. 2019 Aug 1;48(4):1219-1227
pubmed: 30977803
Sci Transl Med. 2019 Feb 20;11(480):
pubmed: 30787170
Bull World Health Organ. 2012 Mar 1;90(3):209-218A
pubmed: 22461716
PLoS One. 2021 Jan 4;16(1):e0244921
pubmed: 33395431
Sci Data. 2017 Jan 31;4:170004
pubmed: 28140397
MMWR Suppl. 1988 May 6;37(5):1-18
pubmed: 3131659
MMWR Recomm Rep. 2001 Jul 27;50(RR-13):1-35; quiz CE1-7
pubmed: 18634202